Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours
Figure 6
Flow cytometric “FACS” peripheral blood lymphocyte CD marker patterns following cellular gene therapy in human cancers. (a) glioblastoma multiforme; (b) hepatocarcinoma; (c) colon adenocarcinoma; (d) ovarian carcinoma; (e) uterine adenocarcinoma; (f) prostate adenocarcinoma. CD molecules were labelled in peripheral blood lymphocytes (PBLs) obtained from prevaccinated and “vaccinated” cancer patients. Each of the first column corresponds to data obtained before vaccinations; each second and third column corresponds to data obtained after one and two successive cellular vaccinations (IGF-I antisense/triple helix cells). Two cases of each of the designated cancers were examined (bar graphs represent the median value of the two cases). Data are expressed as percent of positive cells when compared to the isotype control. Difference in percentage of CD8+ CD11b− and CD8+ CD28+ subpopulations before and after vaccination was strongly significant with a range of from 0.001 to 0.02 according to the Student’s -test and weakly significant concerning the decreasing CD8+ CD11b+ subpopulation from the relevant patients. The value for CD8+, CD8+28+, and CD8+11b− (below 0.01) is illustrated in the bar graph for statistical significance. (The original FACS data concerning PBL cells are in the archives of Collegium Medicum of Nicolas Copernic University, Bromberg, Poland; FACS data () corresponding to the labeling of CD3, CD4, CD5, CD8, CD8+11b+, CD8+11b−, CD8+28+, CD19, CD3−(16 + 56) + (NK), CD25, CD44, and CD45.)
